Clinical Trials Sponsored by Cereneo AG

Total 2416 results

Cereneo AG

Completed

Feedback and Rewards to Increase Motivation for Therapy in Stroke Rehabilitation

Stroke

Switzerland
Cereneo AG

Terminated

Investigating Adherence to Cereneo Tele-service Support After Clinical Disharge in Stroke Patients

Stroke, Ischemic

Switzerland
Cereneo AG
cereneo Institute for Interdsciplinary Research (cefir)

Completed

Survey of Lifelong Food and Nutrition Assistance (LIFANA) in Stroke Patients and Caregivers

Stroke | Diet Modification | Relatives

Switzerland
Cereneo AG
University of Zurich

Terminated

ArmeoSenso - Reward

Stroke

Switzerland
Christian Baumann
Cereneo AG

Unknown

Acoustic Cueing During Slow-wave Sleep as a Measure to Improve Motor Rehabilitation Outcome in Stroke Patients

Stroke

Switzerland
Kai Lutz, PhD
University of Zurich

Completed

Rewarding Feedback in Motor Learning and Rehabilitation (KFSP-REWARD)

Motor Learning | Motor Performance

Switzerland
Cereneo AG
University of Zurich; Swiss Federal Institute of Technology; Swiss Commission... and other collaborators

Terminated

Advanced Robotic Training With Additional Degrees of Freedom: Towards a Free-walking System (LOKOMAT)

Post Stroke Gait Training

Switzerland
Cereno Scientific AB

Completed

Study Investigation Pharmacokinetics and Pharmacodynamics of CS1

Thrombosis

Sweden
Cerevel Therapeutics, LLC

Recruiting

Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing

Opioid Use Disorder

United States
Cerevel Therapeutics, LLC

Recruiting

A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Schizophrenia

United States, Bulgaria
Cerevel Therapeutics, LLC

Recruiting

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy

Apathy in Dementia

United States, Canada
Cerevel Therapeutics, LLC

Completed

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

Healthy Volunteers

United States
Cerevel Therapeutics, LLC

Active, not recruiting

Fixed-Dose Trial in Early Parkinson's Disease (PD) (TEMPO-1)

Parkinson Disease

Spain, United States, Australia, Bulgaria, Canada, Czechia, France, Germany, Israel, Italy, Poland, Ukraine
Cerevel Therapeutics, LLC

Completed

Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants

Healthy Participants

United States
Cerevel Therapeutics, LLC

Active, not recruiting

The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants

Healthy

United States
Cerevel Therapeutics, LLC

Completed

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Hepatic Impairment

United States
Cerevel Therapeutics, LLC

Completed

Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia

Schizophrenia | Blood Pressure

United States
Cerevel Therapeutics, LLC

Completed

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

Schizophrenia

United States
Cerevel Therapeutics, LLC

Completed

A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia

Schizophrenia

United States
Cerevel Therapeutics, LLC

Completed

An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects

Healthy Subjects

United States
Cerenis Therapeutics, SA

Completed

Exploratory Study of Plaque Regression (EXPRESS)

Heterozygous Familial Hypercholesterolemia

Canada
Cereve, Inc.

Completed

Comparison of Two Temperatures to Treat Insomnia

Primary Insomnia

United States
Cereve, Inc.

Completed

30 Days in Home Use and Home Use Patterns Over 6 Months

Primary Insomnia

United States
Cerevel Therapeutics, LLC

Not yet recruiting

A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants

Healthy Participants

United States
Cerevel Therapeutics, LLC

Not yet recruiting

A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants

Healthy Participants
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

Renal Impairment

United States
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine

Hepatic Impairment

United States
Cerevel Therapeutics, LLC

Recruiting

A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants

Healthy Participants

United States
Cerevel Therapeutics, LLC

Recruiting

A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease

Healthy Participants | Alzheimer's Disease Dementia

United States
Cerevel Therapeutics, LLC

Active, not recruiting

A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Seizures

United States, Spain, Australia, Serbia, Poland, Ukraine
Cerevel Therapeutics, LLC

Enrolling by invitation

Open-label Trial in Parkinson's Disease (PD) (TEMPO-4)

Parkinson Disease

Poland, United States, Spain, Australia, Bulgaria, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Serbia, Ukraine
Cerevel Therapeutics, LLC

Active, not recruiting

Flexible-Dose Trial in Early Parkinson's Disease (PD) (TEMPO-2)

Parkinson Disease

Poland, Spain, United States, France, Germany, Hungary, Italy, Serbia, Ukraine, Australia, Korea, Republic of, Taiwan, Thailand
Cerevel Therapeutics, LLC

Completed

Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Participants

Healthy

United States
Cerevel Therapeutics, LLC

Completed

A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease

Parkinson Disease

United States
Bottneuro AG
Hemex AG

Active, not recruiting

Evaluate the Safety and Feasibility of tACS With the Miamind Neurostimulator in Healthy Participants (MindStim)

Healthy Participants | Healthy Population

Switzerland
Santersus AG
ISS AG

Not yet recruiting

Safety, Tolerability and Performance of the NucleoCapture Device in the Reduction of Circulating cfDNA/NETs in Subjects With Sepsis (NUC-CAP)

Sepsis | Respiratory Failure

United Kingdom, Germany, Switzerland
SynDermix AG
ISS AG

Withdrawn

Safety and Efficacy of SDX-3101 for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) (SDX-3101)

Chronic Rhinosinusitis Without Nasal Polyps

Germany, Austria, Switzerland
Tetec AG
Aesculap AG

Completed

Observational Study With NOVOCART® Inject in the Reconstruction of the Hip Joint With Full Thickness Cartilage Defects (HIP-ACTION)

Cartilage Disease

Germany
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder

Panic Disorder

United States
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

Schizophrenia

United States, Bulgaria, Hungary, Puerto Rico, Ukraine
Cerevel Therapeutics, LLC

Recruiting

A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Schizophrenia

United States, Bulgaria, Hungary
Cerevel Therapeutics, LLC

Completed

A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants

Healthy Participants

United States
Cerevel Therapeutics, LLC

Completed

Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)

Parkinson Disease

Germany, Spain, United States, Australia, Bulgaria, Czechia, France, Israel, Italy, Poland, Ukraine, Serbia
Cerevel Therapeutics, LLC

Completed

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

Renal Impairment

United States
Cerevel Therapeutics, LLC

Enrolling by invitation

An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Seizures

United States, Spain, Australia, Poland, Ukraine
Cerevel Therapeutics, LLC

Completed

Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease

Parkinson Disease

United States
Cerevel Therapeutics, LLC

Completed

PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

Schizophrenia

Belgium, United States
Berendo Scientific, LLC

Completed

SleepFlexTM Treatment of Obstructive Sleep Apnea

Obstructive Sleep Apnea

United States
Cerevel Therapeutics, LLC

Completed

Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants

Parkinson Disease

United States
Cerevel Therapeutics, LLC

Completed

A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants

Major Depressive Disorder

United States

3

Subscribe